Merkel Cell Carcinoma Stages

Key Takeaways

• Merkel cell carcinoma (MCC) is staged using the TNM system, which evaluates tumor size, lymph node involvement, and distant spread.
• Stages range from Stage 0 (in situ) to Stage IV (distant metastasis), with each stage reflecting increasing disease severity.
• Early-stage MCC (Stages I and II) is generally more treatable, while advanced stages carry a significantly lower survival rate.
• Five-year relative survival rates drop sharply from approximately 75–80% at Stage I to around 20% or less at Stage IV.
• Accurate staging requires imaging, sentinel lymph node biopsy, and pathological evaluation.

How Is Merkel Cell Carcinoma Staged: The TNM System Explained

Oncologists classify MCC using the Merkel cell carcinoma TNM staging system, a standardized framework developed by the American Joint Committee on Cancer (AJCC). TNM stands for Tumor (T), Node (N), and Metastasis (M), with each component assessed independently before an overall stage is assigned. The eighth edition of the AJCC Cancer Staging Manual, published in 2017, introduced refined criteria that more precisely reflect the behavior of this malignancy.

The “T” category describes the primary tumor’s size and extent of local invasion. Tumors measuring 2 centimeters or less are classified as T1, while those larger than 2 cm are T2 or T3 depending on size, and T4 denotes invasion into deep structures such as fascia, muscle, cartilage, or bone. Accurate tumor measurement at the time of excision or biopsy is therefore critical for correct staging.

The “N” category evaluates regional lymph node involvement and distinguishes between clinically detected nodes (those identified by physical examination or imaging) and pathologically detected nodes (found via sentinel lymph node biopsy). This distinction matters because patients with pathologically detected nodal disease generally have a better prognosis than those with clinically apparent nodal involvement, despite both falling within Stage III. The “M” category is straightforward: M0 indicates no distant spread, while M1 confirms metastasis to distant organs such as the liver, lungs, brain, or distant skin sites.

Merkel Cell Carcinoma Stages: Stage 0 Through Stage IV Differences

The stages of Merkel cell carcinoma explained in clinical practice span from Stage 0 to Stage IV, each carrying distinct anatomical and prognostic implications. Stage 0, also called in situ carcinoma, means abnormal Merkel cells are confined to the epidermis and have not breached the basement membrane. This earliest stage is relatively uncommon at diagnosis because MCC tends to grow rapidly.

Stages I and II both describe localized disease—cancer confined to the primary tumor site without regional lymph node involvement. The key distinction lies in tumor diameter: Stage I tumors are 2 cm or smaller, whereas Stage II tumors exceed 2 cm or demonstrate invasion into adjacent structures. Stage III represents regional spread, encompassing any tumor size accompanied by lymph node involvement, whether detected clinically or pathologically. Stage IV is defined by distant metastasis regardless of the primary tumor’s characteristics.

The table below summarizes the principal Merkel cell carcinoma stage 1 2 3 4 differences along with their defining criteria:

It is worth noting that even within a single stage, disease behavior can vary considerably. Stage III, for instance, encompasses scenarios ranging from a microscopic lymph node deposit found only on sentinel biopsy to bulky, clinically palpable nodal disease—circumstances that carry meaningfully different outcomes. Clinicians therefore consider substage designations (IIIa versus IIIb) when counseling patients and planning treatment.

Early vs. Advanced Merkel Cell Carcinoma: What Each Stage Means

Early vs. advanced stage Merkel cell carcinoma is a distinction that profoundly affects both treatment strategy and expected outcomes. Early-stage disease—Stages I and II—is localized, meaning it has not yet traveled beyond the primary tumor site. At these stages, surgical excision with wide margins, often combined with adjuvant radiation therapy, forms the cornerstone of management. Because the tumor is contained, the goal of therapy is curative, and most patients are candidates for definitive local treatment.

Advanced MCC, encompassing Stage III and Stage IV, presents a fundamentally different clinical picture. Regional nodal disease at Stage III requires more extensive surgery, often including lymph node dissection, combined with radiation and, increasingly, systemic immunotherapy. Immune checkpoint inhibitors—particularly PD-1 and PD-L1 inhibitors such as avelumab and pembrolizumab—have demonstrated durable responses in eligible patients and are now integrated into National Comprehensive Cancer Network (NCCN) guidelines for advanced disease.

Stage IV disease, characterized by distant metastasis, is generally not curable with current therapies, though systemic immunotherapy has extended median survival in a meaningful subset of patients. The rapid pace at which MCC can advance from a localized lesion to distant spread underscores the importance of early detection and prompt staging workup. Dermatologists and oncologists typically recommend whole-body imaging—PET-CT or CT of the chest, abdomen, and pelvis—at diagnosis to rule out occult metastatic disease.

• Stage I/II (Early): Localized tumor; surgery and radiation often curative in intent.
• Stage III (Regional): Lymph node involvement; multimodal therapy required, including possible immunotherapy.
• Stage IV (Distant): Metastatic spread; systemic immunotherapy is the primary treatment approach.

Merkel Cell Carcinoma Staging and Survival Rates by Stage

Merkel cell carcinoma staging and survival rates are closely linked, with five-year relative survival declining significantly as stage advances. According to data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, patients with localized disease (Stage I) have a five-year relative survival rate of approximately 75–80%. This figure reflects outcomes when the cancer is detected and treated before it spreads beyond the primary site.

When MCC has extended to regional lymph nodes (Stage III), five-year survival drops to the range of 45–55%, depending on the extent of nodal involvement and whether nodes were detected clinically or pathologically. Pathologically detected nodal disease carries a more favorable outlook than clinically apparent nodal disease, a distinction captured in the AJCC substaging criteria. Patients with Stage II disease fall between these benchmarks, typically achieving five-year survival rates in the 55–65% range.

Stage IV MCC carries the poorest prognosis, with historical five-year survival rates below 20%. However, the introduction of PD-L1 inhibitors and other immunotherapeutic agents has begun to shift these outcomes for select patients. Clinical trials continue to evaluate combination strategies, including immunotherapy paired with radiation or targeted agents, aiming to improve disease control in the metastatic setting. Patients are encouraged to discuss participation in clinical trials with their oncology team, as MCC’s rarity means that trial data are vital to advancing the field.

It is important to recognize that survival statistics reflect population-level averages and do not predict individual outcomes. Age, immune status, Merkel cell polyomavirus (MCPyV) status, and the extent of treatment all influence how any one patient will respond. Immunocompromised individuals—including organ transplant recipients and those with HIV—tend to have more aggressive disease, which may affect staging workup and treatment intensity.

Frequently Asked Questions

At what stage is Merkel cell carcinoma most commonly diagnosed?

MCC is most commonly diagnosed at Stage I or II, meaning the tumor is still localized to the skin. However, because MCC grows quickly and can be mistaken for a benign lesion, a significant proportion of patients—estimated at roughly 26–36%—already have regional or distant spread at diagnosis. Early biopsy of any rapidly growing, painless skin nodule is critical for catching the disease at a more manageable stage.

Does the Merkel cell polyomavirus status affect staging or prognosis?

Merkel cell polyomavirus (MCPyV) is detected in approximately 80% of MCC tumors and is associated with a relatively more favorable prognosis compared with virus-negative tumors. However, MCPyV status is not a formal component of the AJCC TNM staging system; staging is determined solely by tumor size, nodal involvement, and metastasis. That said, oncologists consider virus status alongside stage when discussing immunotherapy candidacy and expected treatment response.

Can Merkel cell carcinoma be cured if caught at an early stage?

Cure is a realistic goal for many patients diagnosed at Stage I, where five-year survival approaches 75–80% with appropriate treatment. Wide local excision combined with adjuvant radiation therapy is the standard approach for early-stage disease and offers the best chance of long-term disease control. Regular follow-up every three to six months for the first three years is essential, as MCC has a high recurrence risk even after successful initial treatment.